Renovion, Inc.
Renovion is a clinical-stage pharmaceutical company dedicated to restoring lung health through innovative therapies. Their primary focus is on developing ARINA·1, a nebulized therapy that clears mucus, reduces inflammation, and inhibits bacterial growth in the lungs. The company aims to treat diseases such as lung transplant rejection, non-cystic fibrosis bronchiectasis, chronic bronchitis, and other pulmonary conditions characterized by mucus accumulation and inflammation. Renovion's mission is to improve quality of life and clinical outcomes for patients with serious lung diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Treatment of respiratory tract diseases and infections with ascorbic acid compositions
US-11602555-B2
View Details
Treatment of respiratory tract diseases and infections with ascorbic acid compositions
US-11602555-B2
View DetailsProducts
Investigational nebulized mucolytic therapy (nebulizer-delivered inhalation solution)
A sterile buffered inhalation solution developed to restore mucus clearance, reduce airway inflammation, and provide antibacterial activity when delivered via a mesh-optimized nebulizer. Product development includes clinical evidence from early trials, ongoing Phase 2 programs in chronic airway diseases, and use under special-access conditions for some patients.
Investigational nebulized mucolytic therapy (nebulizer-delivered inhalation solution)
A sterile buffered inhalation solution developed to restore mucus clearance, reduce airway inflammation, and provide antibacterial activity when delivered via a mesh-optimized nebulizer. Product development includes clinical evidence from early trials, ongoing Phase 2 programs in chronic airway diseases, and use under special-access conditions for some patients.
Services
Design, execution, and oversight of Phase 1–3 clinical programs for inhaled therapies, including site coordination, endpoint selection, and regulatory reporting.
Use of simulation software to optimize study design, statistical powering, and endpoint selection prior to trial initiation.
Engagement with disease foundations and registries to inform trial design, endpoints, and patient recruitment strategies.
Management of university licensing relationships and use of academic grant support and commercialization resources to advance early-stage assets.
Design, execution, and oversight of Phase 1–3 clinical programs for inhaled therapies, including site coordination, endpoint selection, and regulatory reporting.
Use of simulation software to optimize study design, statistical powering, and endpoint selection prior to trial initiation.
Engagement with disease foundations and registries to inform trial design, endpoints, and patient recruitment strategies.
Management of university licensing relationships and use of academic grant support and commercialization resources to advance early-stage assets.
Expertise Areas
- Clinical trial management for pulmonary and transplant indications
- Inhalation therapy and aerosol delivery development
- Formulation development for nebulized mucolytic therapies
- Biomarker development and sputum rheology analysis
Key Technologies
- Mesh nebulizer aerosol delivery optimization
- Nebulized sterile buffered mucolytic formulations
- Mucociliary clearance and mucus transport assays
- Sputum rheology testing
News & Updates
Renovion announced the enrollment of the first patient in a Phase 3 trial for ARINA-1, a therapy aimed at preventing bronchiolitis obliterans syndrome (BOS) in lung transplant patients.
Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in LT
The FDA has granted Fast Track designation to ARINA-1 for the prevention of BOS progression in lung transplant patients, accelerating its regulatory review process.
Renovion announced the completion of patient enrollment for its Phase 2 CLIMB study evaluating ARINA·1 in bronchiectasis patients.
The company reported significant symptom improvement and quality of life enhancement in patients treated with ARINA·1 in a Phase 2 trial.
Robust data show significant symptom improvement surpassing clinical thresholds in NCFBE patients treated with ARINA-1.
Patient enrollment for the Phase 2 trial targeting bronchiectasis has been completed.
Renovion announced the enrollment of the first patient in a Phase 3 trial for ARINA-1, a therapy aimed at preventing bronchiolitis obliterans syndrome (BOS) in lung transplant patients.
Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in LT
The FDA has granted Fast Track designation to ARINA-1 for the prevention of BOS progression in lung transplant patients, accelerating its regulatory review process.
Renovion announced the completion of patient enrollment for its Phase 2 CLIMB study evaluating ARINA·1 in bronchiectasis patients.
The company reported significant symptom improvement and quality of life enhancement in patients treated with ARINA·1 in a Phase 2 trial.
Robust data show significant symptom improvement surpassing clinical thresholds in NCFBE patients treated with ARINA-1.
Patient enrollment for the Phase 2 trial targeting bronchiectasis has been completed.